Close

Brainstorm Cell Therapeutics (BCLI) Announces Phase 3 Trial of NurOwn in ALS Now Open to Canadian Patients

March 28, 2018 6:00 AM EDT Send to a Friend
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announces that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login